FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), applying innovative diagnostics to transform disease management and improve patient outcomes, today announced it has ...

FRIENDSWOOD, Texas, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, ...

Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating ...

Guggenheim raised the firm’s price target on Castle Biosciences (CSTL) to $43 from $30 and keeps a Buy rating on the shares. The firm adjusted its ...

Castle Biosciences, Inc. is promoting Skin Cancer Awareness Month this May by partnering with organizations such as IMPACT Melanoma, AIM at Melanoma, and the Melanoma Research Foundation to enhance ...

The MarketWatch News Department was not involved in the creation of this content. FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving ...

Castle Biosciences, Inc. has achieved multiple accolades in the 2025 Top Workplaces program, including its third consecutive national Healthcare Industry Top Workplaces award, ranking third in its ...

The company raised 2025 total revenue guidance to $310 million–$320 million. Stokes explained that “our normalized revenue growth range in 2025 would be approximately 21% to 26%” when excluding ...

Castle Biosciences ((CSTL)) has held its Q3 earnings call. Read on for the main highlights of the call. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, ...

Castle reported stronger Q2 revenue growth and a lower net loss than analysts anticipated. The company also raised its full-year revenue outlook. Castle reported Q2 revenue of $50 million, a year-over ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive ...